open access

Vol 3, No 1 (2018)
CASE REPORT
Published online: 2018-06-12
Get Citation

ACUTE INTOXICATION DUE TO DESIGNER DRUG TALISMAN — TREATMENT DILEMMA IN PRE-HOSPITAL SETTINGS — CASE REPORT AND REVIEW

Wojciech Wieczorek, Halla Kaminska, Pawel Wieczorek, Lukasz Szarpak
DOI: 10.5603/DEMJ.2018.0007
·
Pubmed: 6342813
·
Disaster Emerg Med J 2018;3(1):31-35.

open access

Vol 3, No 1 (2018)
CASE REPORT
Published online: 2018-06-12

Abstract

 Currently, the number of novel psychoactive substances (NPS) has significantly increased. Recent reports on the abuse of synthetic cathinones focus on serious physical and psychological risks resulting from their consumption, thereby emphasising that a growing use of these drugs might constitute an important public health. Case report: A young man presented to the emergency department with acute designer drug intox­ication complicated with severe respiratory failure. Why should an emergency physician be aware of this? We observe a growing use of NPS among young people. Further studies describing clinical manifestations of intoxication and toxicity of synthetic cathinones and treatment guidelines are still needed.

Abstract

 Currently, the number of novel psychoactive substances (NPS) has significantly increased. Recent reports on the abuse of synthetic cathinones focus on serious physical and psychological risks resulting from their consumption, thereby emphasising that a growing use of these drugs might constitute an important public health. Case report: A young man presented to the emergency department with acute designer drug intox­ication complicated with severe respiratory failure. Why should an emergency physician be aware of this? We observe a growing use of NPS among young people. Further studies describing clinical manifestations of intoxication and toxicity of synthetic cathinones and treatment guidelines are still needed.

Get Citation

Keywords

Talisman, designer drug, synthetic cathinones, treatment guidelines

About this article
Title

ACUTE INTOXICATION DUE TO DESIGNER DRUG TALISMAN — TREATMENT DILEMMA IN PRE-HOSPITAL SETTINGS — CASE REPORT AND REVIEW

Journal

Disaster and Emergency Medicine Journal

Issue

Vol 3, No 1 (2018)

Pages

31-35

Published online

2018-06-12

DOI

10.5603/DEMJ.2018.0007

Pubmed

6342813

Bibliographic record

Disaster Emerg Med J 2018;3(1):31-35.

Keywords

Talisman
designer drug
synthetic cathinones
treatment guidelines

Authors

Wojciech Wieczorek
Halla Kaminska
Pawel Wieczorek
Lukasz Szarpak

References (20)
  1. Advisory Council on the Misuse of Drugs (ACMD). (2011). Consideration of the Novel Psychoactive Substances (‘Legal highs’). https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119139/acmdnps2011.pdf.
  2. http://www.emcdda.europa.eu/.
  3. http://gis.gov.pl/en/.
  4. http://www.mz.gov.pl/en/.
  5. Report of the Chief Sanitary Inspectorate of the drug substitutes- together against ‘legal highs’ 2013-2014, Chief Sanitary Inspectorate, Warsaw, 2014. http://www.gis.gov.pl/ckfinder/userfiles/files/BI/GIS_raport_2013-2014.pdf (30.10.2015).
  6. EMCDDA, 2010a. EMCDDA and Europol step up information collection on mephedrone. http://www.emcdda.europa.eu/Vol.,ed.eds.
  7. Coppola M, Mondola R. 5-Iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects. Toxicol Lett. 2013; 218(1): 24–29.
  8. US Drug Enforcement Administration, 2012. US Drug Enforcement Administration Office of Diversion Control. National Forensic Laboratory Information System: year 2011 annual report. In: Administration USDE, editor. Springfield, VA 2012.
  9. Adamowicz P, Tokarczyk B, Stanaszek R, et al. Fatal intoxication with 3-methyl-N-methylcathinone (3-MMC) and 5- (2-aminopropyl) benzofuran (5-APB). Forensic Sci. Int. 2014; 245C: 126.
  10. Hunter LJ, Dargan PI, Benzie A, et al. Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM. Postgrad Med J. 2014; 90(1061): 133–138.
  11. Corkery JM, Elliott S, Schifano F, et al. 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39(2): 253–258.
  12. Drummond A. Study on the Prevalence of Drug Use, Including Intravenous Drug Use, and Blood-borne Viruses Among Irish Prisoners Population. National Advisory Committee on Drugs and Alcohol, Dublin 2014: 38–41.
  13. EMCDDA, 2010c. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone). In accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk-assessment and control of new psychoactive substances.
  14. EMCDDA, 2014. European Monitoring Centre for Drugs and Drug Addiction.
  15. German CL, Fleckenstein AE, Hanson GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 2014; 97(1): 2–8.
  16. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013; 168(2): 458–470.
  17. Simmler LD, Rickli A, Hoener MC, et al. Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology. 2014; 79: 152–160.
  18. Motbey CP, Hunt GE, Bowen MT, et al. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol. 2012; 17(2): 409–422.
  19. Coppola M, Mondola R. 4-methylamphetamine (4-MA): chemistry, pharmacology and toxicology of a new potential recreational drug. Mini Rev Med Chem. 2013; 13(14): 2097–2101.
  20. Katselou MG, Matralis AN, Kourounakis AP. Multi-target drug design approaches for multifactorial diseases: from neurodegenerative to cardiovascular applications. Curr Med Chem. 2014; 21(24): 2743–2787.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl